Ackman's Pershing Square Hedge Fund Rises 27 Percent Through July

Monday, 04 Aug 2014 03:45 PM


  Comment  |
   Contact Us  |
|  A   A  
  Copy Shortlink
Billionaire investor William Ackman's Pershing Square Holdings has risen 27.2 percent this year, according to an investor in the fund, after extending its gains modestly last month when many hedge fund managers suffered losses.

The Pershing Square Holdings fund inched up 0.6 percent in July. Performance at Ackman's $15 billion firm has long been watched closely, but never more so than now as he fights to seal a deal between drug companies Allergan Inc. and Valeant Pharmaceuticals International Ltd. He also periodically presents new information to underscore his argument that nutrition and diet company Herbalife Ltd. is running a pyramid scheme, something the company denies.

Performance numbers from other fund managers, including Daniel Loeb's Third Point, which fell 1.2 percent last month but remains up 4.7 percent year to date, show that July was a tough month for many hedge funds. The broader stock market sold off late in the month amid growing fears about U.S. interest rates and geopolitical concerns.

This year's returns rank Ackman among the industry's best performers and underscore just how much his portfolio has recovered from a year ago, when his short bet against Herbalife and a failed long position on retailer J.C. Penney took a bite out of returns. He exited the Penney bet in August 2013. Meanwhile, holdings such as Air Products & Chemicals Inc. and Canadian Pacific Railway Ltd. fared well last month.

The last few weeks have been eventful for the activist investor. He publicly ended a long-running feud with rival Carl Icahn with a hug, and a week later choked back tears during a fizzled presentation on Herbalife, when he called the company a criminal enterprise and compared it to drug dealers, failed energy company Enron and the Nazis.

On Friday, Botox maker Allergan accused Ackman, its biggest investor, of breaking insider trading laws while working with rival Valeant Pharmaceuticals.

© 2014 Thomson/Reuters. All rights reserved.

  Comment  |
   Contact Us  |
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
Zip Code:
Privacy: We never share your email.
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
You May Also Like

Stocks Fall as Slumping Oil Prices Push Energy Industry Lower

Tuesday, 25 Nov 2014 16:57 PM

A slump in energy prices pushed the stock market back from record levels on Tuesday. Energy stocks slid as the price of  . . .

Peter Schiff: US 'Headed to Recession' With More QE, Pricey Oil

Tuesday, 25 Nov 2014 16:00 PM

"The U.S. economy is headed to a recession, which means we're going to get more QE [quantitative easing], not a rate hik . . .

Yale's Shiller 'Somewhat Optimistic' Despite 'Slow Season' for Housing

Tuesday, 25 Nov 2014 15:27 PM

The latest price data on the housing market show that it's slowing down, says Nobel laureate economist Robert Shiller of . . .

Most Commented
Top Stories

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

America's News Page
©  Newsmax Media, Inc.
All Rights Reserved